Latest News by Industry
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Nov 8, 2022--
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today reported financial results for the third quarter ended September 30, 2022 and provided a business update.
“This quarter we reported strong top-line growth and continued to gain market share while carefully managing our operating expenses as we advance toward profitability,” said David Moatazedi, President and Chief Executive Officer. “Demand for Jeuveau ® remained strong even with anticipated seasonality and the return of summer travel. We remain confident we can achieve the top end of our 2022 sales guidance range of $143 to $150 million equating to a year-over-year growth rate of approximately 50%, which is roughly triple the projected toxin market growth rate.”
Moatazedi continued, “Perhaps the most significant highlight of the third quarter was the highly successful launch of our ‘Switch Your Tox’ promotional campaign. ‘Switch Your Tox’ helped drive an above-market 27% year-over-year growth rate, and when factoring for the above-normal deferred revenue this campaign required, our growth rate would have been even stronger. This campaign also helped generate the largest number of new accounts we have added in three years and drove a record 100,000 consumer redemptions in our loyalty program in the quarter. Importantly, ‘Switch Your Tox’ redemptions will continue through year-end, providing continued momentum into the fourth quarter.”
Third Quarter 2022 Highlights and Recent Developments
Third Quarter 2022 Financial Results
Outlook
Conference Call Information
Management will host a conference call and live webcast to discuss Evolus’ financial results today at 4:30 p.m. ET. To participate in the conference call, dial (877) 407-6184 (U.S.) or (201) 389-0877 (international) or connect to the live webcast via the link on the Investor Relations page of our website at www.evolus.com.
Following the completion of the call, an audio replay can be accessed for 48 hours by dialing (877) 660-6853 (U.S.) or (201) 612-7415 (international) and using conference number 13733400. An archived webcast, which will remain available for 30 days, can also be accessed on the Investor Relations page of our website at www.evolus.com.
About Evolus, Inc.
Evolus (Nasdaq: EOLS) is a performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global, multi-product aesthetics company based on our flagship product, Jeuveau ® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Visit us at www.evolus.com, and follow us on LinkedIn, Twitter, Instagram or Facebook.
Forward-Looking Statements
This press release contains forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, including statements based on our current expectations, assumptions, estimates and projections about future events, our business, financial condition, results of operations and prospects, our industry and the regulatory environment in which we operate. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative of those terms, or other comparable terms intended to identify statements about the future. The company’s forward-looking statements include, but are not limited to, statements related to the company’s financial outlook for 2022, expectations regarding the company’s cash position and expectations regarding share growth, market conditions, international product launches and our ongoing clinical trial.
The forward-looking statements included herein are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements. These risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond our control, include, but are not limited to uncertainties associated with our ability to comply with the terms and conditions in the Allergan/Medytox Settlement Agreements, our ability to fund our future operations or obtain financing to fund our operations, the continued impact of COVID-19 or other outbreaks of contagious diseases on our business, unfavorable global economic conditions and the impact on consumer discretionary spending, uncertainties related to customer and consumer adoption of Jeuveau ®, the efficiency and operability of our digital platform, competition and market dynamics, our ability to successfully launch and commercialize our products in new markets, our ability to maintain regulatory approvals of Jeuveau ® or obtain regulatory approvals for new product candidates or indications and other risks described in our filings with the Securities and Exchange Commission, including in the section entitled “Risk Factors” in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 filed with the Securities and Exchange Commission on August 2, 2022. These filings can be accessed online at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information, changed circumstances or unanticipated events. If we do update or revise one or more of these statements, investors and others should not conclude that we will make additional updates or corrections.
Use of Non-GAAP Financial Measures
Evolus’ financial results are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). This press release and the reconciliation tables included in the financial schedules below include adjusted gross profit, adjusted gross profit margin, non-GAAP operating expenses and non-GAAP loss from operations. Adjusted gross profit is calculated as gross profit excluding amortization of an intangible asset and, as applicable, the one-time settlement payment from Daewoong. Adjusted gross profit margin is defined as adjusted gross profit as a percentage of total net revenues. Non-GAAP operating expenses and non-GAAP loss from operations exclude (i) product cost of sales, in the case of non-GAAP operating expenses only, (ii) in-process research and development, (iii) one-time settlement payment from Daewoong, (iv) the revaluation of contingent royalty obligations, (v) stock-based compensation expense, and (vi) depreciation and amortization. Beginning in the fourth quarter of 2021, Evolus began excluding product cost of sales from its presentation of non-GAAP operating expenses; prior period amounts have been revised to conform to the current presentation. Management believes that adjusted gross profit margin is an important measure for investors because management uses adjusted gross profit margin as a key performance indicator to evaluate the profitability of sales without giving effect to costs that are not core to our cost of sales, such as the settlement payment from Daewoong, and the amortization of an intangible asset. Management believes that non-GAAP operating expenses and non-GAAP loss from operations are useful in helping to identify the company’s core operating performance and enables management to consistently analyze the period-to-period financial performance of the core business operations. Management also believes that non-GAAP operating expenses and non-GAAP loss from operations will enable investors to assess the company in the same way that management has historically assessed the company’s operating expenses against comparable companies with conventional accounting methodologies. The company’s definitions of adjusted gross profit, adjusted gross profit margin, non-GAAP operating expenses and non-GAAP loss from operations have limitations as analytical tools and may differ from other companies reporting similarly named measures. Non-GAAP measures should not be considered measures of financial performance under GAAP, and the items excluded from such non-GAAP measures should not be considered in isolation or as alternatives to financial statement data presented in the financial statements as an indicator of financial performance or liquidity. Non-GAAP measures should be considered in addition to results prepared in accordance with GAAP but should not be considered a substitute for or superior to GAAP results.
For a reconciliation of our historical adjusted gross profit margin, non-GAAP operating expenses and non-GAAP loss from operations presented herein to gross profit margin, GAAP operating expenses and GAAP loss from operations, the most directly comparable GAAP financial measures, please see “Reconciliation of Gross Profit Margin to Adjusted Gross Profit Margin,” “Reconciliation of GAAP Operating Expenses to Non-GAAP Operating Expenses” and “Reconciliation of GAAP (Loss) from Operations to Non-GAAP (Loss) from Operations” in the financial schedules below. In addition, this press release includes information regarding the company’s expected adjusted gross profit margin and non-GAAP operating expenses for full year 2022. Evolus has not provided a reconciliation of such forward-looking non-GAAP adjusted gross profit margin or non-GAAP operating expenses because a reconciliation of such measures to GAAP gross profit margin and GAAP operating expenses, respectively, the most directly comparable GAAP financial measures, is not available without unreasonable efforts. This is due to the inherent difficulty of forecasting the timing or amount of various reconciling items that would impact the forward-looking adjusted gross profit margin and non-GAAP operating expenses outlook that have not yet occurred and/or cannot be reasonably predicted. Such unavailable information could have a significant impact on Evolus’ GAAP financial results.
Jeuveau ® and Nuceiva ® are registered trademarks of Evolus, Inc.
Hi-Pure ™ is a trademark of Daewoong Pharmaceutical Co, Ltd.
1 |
| Represents cumulative statistics from the launch of Jeuveau ® in May 2019 through September 30, 2022. |
Evolus, Inc. | |||||||||||||||
| Three Months Ended |
| Nine Months Ended | ||||||||||||
| 2022 |
| 2021 |
| 2022 |
| 2021 | ||||||||
Revenue: |
|
|
|
|
|
|
| ||||||||
Product revenue, net | $ | 33,215 |
|
| $ | 26,677 |
|
| $ | 103,604 |
|
| $ | 64,314 |
|
Service revenue |
| 684 |
|
|
| — |
|
|
| 1,366 |
|
|
| 702 |
|
Total net revenues |
| 33,899 |
|
|
| 26,677 |
|
|
| 104,970 |
|
|
| 65,016 |
|
|
|
|
|
|
|
|
| ||||||||
Operating expenses: |
|
|
|
|
|
|
| ||||||||
Product cost of sales (excludes amortization of intangible assets) |
| 13,490 |
|
|
| 11,490 |
|
|
| 42,517 |
|
|
| 27,700 |
|
Settlement payment from Daewoong |
| — |
|
|
| — |
|
|
| — |
|
|
| (25,500 | ) |
Selling, general and administrative |
| 34,794 |
|
|
| 31,673 |
|
|
| 105,111 |
|
|
| 78,801 |
|
Research and development |
| 1,376 |
|
|
| 301 |
|
|
| 3,394 |
|
|
| 1,641 |
|
In-process research and development |
| — |
|
|
| — |
|
|
| 2,000 |
|
|
| — |
|
Revaluation of contingent royalty obligation payable to |
| 1,216 |
|
|
| 1,400 |
|
|
| 3,946 |
|
|
| 4,049 |
|
Depreciation and amortization |
| 920 |
|
|
| 923 |
|
|
| 2,695 |
|
|
| 4,702 |
|
Total operating expenses |
| 51,796 |
|
|
| 45,787 |
|
|
| 159,663 |
|
|
| 91,393 |
|
Loss from operations |
| (17,897 | ) |
|
| (19,110 | ) |
|
| (54,693 | ) |
|
| (26,377 | ) |
Other income (expense): |
|
|
|
|
|
|
| ||||||||
Interest income |
| 38 |
|
|
| — |
|
|
| 42 |
|
|
| 1 |
|
Interest expense |
| (2,343 | ) |
|
| (311 | ) |
|
| (6,466 | ) |
|
| (1,256 | ) |
Loss from extinguishment of debts, net |
| — |
|
|
| — |
|
|
| — |
|
|
| (968 | ) |
Other expense, net |
| (62 | ) |
|
| — |
|
|
| (93 | ) |
|
| — |
|
Loss before income taxes: |
| (20,264 | ) |
|
| (19,421 | ) |
|
| (61,210 | ) |
|
| (28,600 | ) |
Income tax expense |
| 12 |
|
|
| 12 |
|
|
| 38 |
|
|
| 33 |
|
Net loss | $ | (20,276 | ) |
| $ | (19,433 | ) |
| $ | (61,248 | ) |
| $ | (28,633 | ) |
Other comprehensive gain (loss): |
|
|
|
|
|
|
| ||||||||
Unrealized loss, net of tax |
| (203 | ) |
|
| — |
|
|
| (368 | ) |
|
| — |
|
Comprehensive loss | $ | (20,479 | ) |
| $ | (19,433 | ) |
| $ | (61,616 | ) |
| $ | (28,633 | ) |
Net loss per share, basic and diluted | $ | (0.36 | ) |
| $ | (0.35 | ) |
| $ | (1.09 | ) |
| $ | (0.60 | ) |
Weighted-average shares outstanding used to compute basic and |
| 56,177 |
|
|
| 55,007 |
|
|
| 55,998 |
|
|
| 47,818 |
|
Evolus, Inc. | |||||
| September 30, 2022 |
| December 31, 2021 | ||
Cash and cash equivalents | $ | 65,572 |
| $ | 146,256 |
Accounts receivable, net |
| 20,920 |
|
| 14,657 |
Inventories |
| 21,565 |
|
| 1,762 |
Prepaid expenses and other current assets |
| 7,889 |
|
| 16,124 |
Total current assets |
| 115,946 |
|
| 178,799 |
Noncurrent assets |
| 76,773 |
|
| 78,684 |
Total assets | $ | 192,719 |
| $ | 257,483 |
Accounts payable and accrued expenses | $ | 38,447 |
| $ | 36,084 |
Accrued litigation settlement |
| 5,000 |
|
| 15,000 |
Other current liabilities |
| 7,824 |
|
| 6,579 |
Total current liabilities |
| 51,271 |
|
| 57,663 |
Accrued litigation settlement |
| — |
|
| 5,000 |
Term loan, net of discount and issuance costs |
| 71,712 |
|
| 71,222 |
Other noncurrent liabilities |
| 40,516 |
|
| 41,722 |
Total liabilities | $ | 163,499 |
| $ | 175,607 |
Total stockholders’ equity | $ | 29,220 |
| $ | 81,876 |
Evolus, Inc. | |||||||||
| Nine Months Ended September 30, | ||||||||
| 2022 | 2021 | |||||||
Net cash (used in) provided by: |
|
|
|
| |||||
Operating activities | $ | (76,138 | ) | * | $ | (24,344 | ) | * | |
Investing activities |
| (1,548 | ) |
|
| 4,420 |
|
| |
Financing activities |
| (2,630 | ) |
|
| 25,158 |
|
| |
Effect of exchange rates on cash |
| (368 | ) |
|
| — |
|
| |
Change in cash and cash equivalents |
| (80,684 | ) |
|
| 5,234 |
|
| |
Cash and cash equivalents, beginning of period |
| 146,256 |
|
|
| 102,562 |
|
| |
Cash and cash equivalents, end of period | $ | 65,572 |
|
| $ | 107,796 |
|
|
* |
| includes a settlement payment of $15.0 million to Allergan/Medytox |
Evolus, Inc. | |||||||||||||||
| Three Months Ended |
| Nine Months Ended | ||||||||||||
| 2022 |
| 2021 |
| 2022 |
| 2021 | ||||||||
Total net revenues | $ | 33,899 |
|
| $ | 26,677 |
|
| $ | 104,970 |
|
| $ | 65,016 |
|
Cost of sales: |
|
|
|
|
|
|
| ||||||||
Product cost of sales (excludes amortization of intangible |
| 13,490 |
|
|
| 11,490 |
|
|
| 42,517 |
|
|
| 27,700 |
|
Settlement payment from Daewoong |
| — |
|
|
| — |
|
|
| — |
|
|
| (25,500 | ) |
Amortization of distribution right intangible asset |
| 739 |
|
|
| 739 |
|
|
| 2,216 |
|
|
| 2,200 |
|
Total cost of sales |
| 14,229 |
|
|
| 12,229 |
|
|
| 44,733 |
|
|
| 4,400 |
|
Gross profit |
| 19,670 |
|
|
| 14,448 |
|
|
| 60,237 |
|
|
| 60,616 |
|
Gross profit margin |
| 58.0 | % |
|
| 54.2 | % |
|
| 57.4 | % |
|
| 93.2 | % |
Add: Settlement payment from Daewoong |
| — |
|
|
| — |
|
|
| — |
|
|
| (25,500 | ) |
Add: Amortization of distribution right intangible asset |
| 739 |
|
|
| 739 |
|
|
| 2,216 |
|
|
| 2,200 |
|
Adjusted gross profit | $ | 20,409 |
|
| $ | 15,187 |
|
| $ | 62,453 |
|
| $ | 37,316 |
|
Adjusted gross profit margin |
| 60.2 | % |
|
| 56.9 | % |
|
| 59.5 | % |
|
| 57.4 | % |
Evolus, Inc. | |||||||||||||||
| Three Months Ended |
| Nine Months Ended |
| Three | ||||||||||
| 2022 |
| 2021 |
| 2022 |
| 2021 |
| 2022 | ||||||
GAAP operating expense | $ | 51,796 |
| $ | 45,787 |
| $ | 159,663 |
| $ | 91,393 |
|
| $ | 58,511 |
Adjustments: |
|
|
|
|
|
|
|
|
| ||||||
Product cost of sales (excludes amortization of |
| 13,490 |
|
| 11,490 |
|
| 42,517 |
|
| 27,700 |
|
|
| 15,819 |
Settlement payment from Daewoong |
| — |
|
| — |
|
| — |
|
| (25,500 | ) |
|
| — |
In-process research and development |
| — |
|
| — |
|
| 2,000 |
|
| — |
|
|
| 2,000 |
Revaluation of contingent royalty obligation |
| 1,216 |
|
| 1,400 |
|
| 3,946 |
|
| 4,049 |
|
|
| 1,414 |
Stock-based compensation: |
|
|
|
|
|
|
|
|
| ||||||
Included in selling, general and administrative |
| 2,398 |
|
| 2,399 |
|
| 8,236 |
|
| 6,784 |
|
|
| 2,924 |
Included in research and development |
| 85 |
|
| 77 |
|
| 185 |
|
| 143 |
|
|
| 55 |
Depreciation and amortization |
| 920 |
|
| 923 |
|
| 2,695 |
|
| 4,702 |
|
|
| 853 |
Non-GAAP operating expense | $ | 33,687 |
| $ | 29,498 |
| $ | 100,084 |
| $ | 73,515 |
|
| $ | 35,446 |
Evolus, Inc. | |||||||||||||||||||
| Three Months Ended |
| Nine Months Ended |
| Three | ||||||||||||||
| 2022 |
| 2021 |
| 2022 |
| 2021 |
| 2022 | ||||||||||
GAAP (loss) from operations | $ | (17,897 | ) |
| $ | (19,110 | ) |
| $ | (54,693 | ) |
| $ | (26,377 | ) |
| $ | (21,348 | ) |
Adjustments: |
|
|
|
|
|
|
|
|
| ||||||||||
Settlement payment from Daewoong |
| — |
|
|
| — |
|
|
| — |
|
|
| (25,500 | ) |
|
| — |
|
Revaluation of contingent royalty obligation |
| 1,216 |
|
|
| 1,400 |
|
|
| 3,946 |
|
|
| 4,049 |
|
|
| 1,414 |
|
In-process research and development |
| — |
|
|
| — |
|
|
| 2,000 |
|
|
| — |
|
|
| 2,000 |
|
Stock-based compensation: |
|
|
|
|
|
|
|
|
| ||||||||||
Included in selling, general and administrative |
| 2,398 |
|
|
| 2,399 |
|
|
| 8,236 |
|
|
| 6,784 |
|
|
| 2,924 |
|
Included in research and development |
| 85 |
|
|
| 77 |
|
|
| 185 |
|
|
| 143 |
|
|
| 55 |
|
Depreciation and amortization |
| 920 |
|
|
| 923 |
|
|
| 2,695 |
|
|
| 4,702 |
|
|
| 853 |
|
Non-GAAP (loss) from operations | $ | (13,278 | ) |
| $ | (14,311 | ) |
| $ | (37,631 | ) |
| $ | (36,199 | ) |
| $ | (14,102 | ) |
View source version on businesswire.com:https://www.businesswire.com/news/home/20221108006039/en/
CONTACT: Investor/Media Contact:
David K. Erickson, Evolus, Inc.
Vice President, Investor Relations
Tel: 949-966-1798
Email:david.erickson@evolus.com
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: LUXURY WOMEN BIOTECHNOLOGY HEALTH COSMETICS CONSUMER PHARMACEUTICAL GENERAL HEALTH RETAIL
SOURCE: Evolus
Copyright Business Wire 2022.
PUB: 11/08/2022 04:05 PM/DISC: 11/08/2022 04:06 PM
http://www.businesswire.com/news/home/20221108006039/en